Pramlintide vs Cagrilintide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Symlin, SymlinPen
Pramlintide (Symlin) is a synthetic version of amylin, the hormone your pancreas releases alongside insulin, and it was the first amylin drug ever approved (FDA, March 2005). It was used as a mealtime add-on for type 1 and type 2 diabetes in people already on mealtime insulin. It never sold well because it meant up to three extra injections a day and a serious hypoglycemia warning, and AstraZeneca has discontinued it in the US. Today it matters mostly as the proof of concept behind newer weekly amylin drugs like cagrilintide and petrelintide.
Also: AM833, NN9838
Cagrilintide (also called AM833) is a long-acting synthetic analog of amylin, the gut-brain satiety hormone co-secreted with insulin by pancreatic beta cells. It is an investigational once-weekly injectable being developed by Novo Nordisk for obesity, most prominently as the amylin half of CagriSema (cagrilintide plus semaglutide). It is not yet approved as a standalone drug, but it has cleared phase 2 trials and is in late-stage development.
Key Comparison Insights
- Pramlintide is FDA approved, while Cagrilintide remains in research stages.
- Pramlintide is categorized as Metabolic, while Cagrilintide is Weight Loss.
- Pramlintide has stronger research evidence (FDA Approved) compared to Cagrilintide (Human Trials).
Detailed Comparison
| Attribute | Pramlintide | Cagrilintide |
|---|---|---|
| Category | Metabolic | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Human amylin clumps into fibrils, which makes it useless as a drug. Pramlintide fixes that by swapping three amino acids (positions 25, 28 and 29) for proline, giving a stable 37-amino-acid analog. It acts on amylin receptors in the brainstem to slow stomach emptying, blunt the glucagon spike after meals, and make you feel full sooner. The result is a smaller blood sugar rise after eating and modestly lower food intake. It is very short-acting (half-life about 48 minutes), so it has to be injected before each major meal. Because it lowers post-meal glucose on top of insulin, the label requires cutting mealtime insulin by 50% when starting. | Cagrilintide is a non-selective agonist of the amylin and calcitonin receptor family. It activates amylin receptors (which are calcitonin receptors paired with RAMP accessory proteins) to signal satiety in the brain, slow gastric emptying, and blunt the post-meal glucagon rise. Mechanistic work in mice shows it reduces body weight mainly through amylin receptors AMY1R and AMY3R acting in the hindbrain, with the area postrema as a key entry point and downstream signaling through the nucleus of the solitary tract and parabrachial nucleus. Notably, weight loss in those studies persisted even after the acute appetite-suppressing effect faded, hinting at effects on energy balance beyond simple food-intake reduction. Chemically it is built on a pramlintide-like 37-amino-acid backbone with substitutions and a fatty-diacid chain attached to extend its half-life to roughly a week, enabling once-weekly dosing. |
| Common Dosing | Type 2: 120 mcg before major meals; Type 1: 30-60 mcg before major meals Before each major meal (2-3 times daily) | 2.4 mg weekly Once weekly |
| Administration | Subcutaneous injection immediately before each major meal (never mixed with insulin in the same syringe) | Subcutaneous injection once weekly |
| Typical Duration | Long-term adjunct to insulin therapy | Long-term / chronic use expected |
| Best Time to Take | Immediately before each major meal | Any consistent time weekly |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Approval came in March 2005 after a rocky path that included a negative FDA advisory vote in 2001 and approvable letters requiring more trials. It is approved as an adjunct for type 1 or type 2 diabetes in people using mealtime insulin who are not at goal despite optimal insulin. Benefits in trials were modest: small HbA1c reductions and some weight loss, rather than the big effects of modern incretin drugs. Side effects are the main story. In type 1 diabetes, nausea hit 48% versus 17% on placebo and anorexia 17% versus 2%; in type 2, nausea was 28% versus 12%. The label carries a boxed warning for severe insulin-induced hypoglycemia, usually within 3 hours of injection, especially in type 1 diabetes. AstraZeneca discontinued SymlinPen in the US, and MedlinePlus (March 2026) states pramlintide injection has been discontinued in the US. Its lasting legacy is scientific: it showed amylin is a real target, which is why the field is now testing long-acting amylin analogs for obesity. | Cagrilintide has real human data, which sets it apart from most peptides in this category. In a 2021 Lancet phase 2 dose-finding trial (Lau et al.), once-weekly cagrilintide at 4.5 mg produced about 10.8% mean body weight loss over 26 weeks, beating both placebo (around 3%) and liraglutide 3.0 mg (around 9%), establishing that amylin agonism alone can drive clinically meaningful weight loss. Its bigger story is combination therapy: paired with semaglutide as CagriSema, it advanced into phase 3 REDEFINE trials for obesity and type 2 diabetes, with reported weight loss in the low 20% range, though final results came in somewhat below the most optimistic expectations. Side effects are dominated by the expected gastrointestinal effects (nausea, vomiting) common to gut-hormone drugs. As of 2026 cagrilintide is investigational and not FDA-approved on its own. The evidence is genuinely human and well-controlled here, which is rare, but it is still a drug under regulatory review rather than an approved therapy. |
Frequently Asked Questions: Pramlintide vs Cagrilintide
What is the difference between Pramlintide and Cagrilintide?
Pramlintide is a metabolic peptide that pramlintide (symlin) is a synthetic version of amylin, the hormone your pancreas releases alongside insulin, and it was the first amylin drug ever approved (fda, march 2005). it was used as a mealtime add-on for type 1 and type 2 diabetes in people already on mealtime insulin. it never sold well because it meant up to three extra injections a day and a serious hypoglycemia warning, and astrazeneca has discontinued it in the us. today it matters mostly as the proof of concept behind newer weekly amylin drugs like cagrilintide and petrelintide. Cagrilintide is a weight loss peptide that cagrilintide (also called am833) is a long-acting synthetic analog of amylin, the gut-brain satiety hormone co-secreted with insulin by pancreatic beta cells. it is an investigational once-weekly injectable being developed by novo nordisk for obesity, most prominently as the amylin half of cagrisema (cagrilintide plus semaglutide). it is not yet approved as a standalone drug, but it has cleared phase 2 trials and is in late-stage development. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Pramlintide or Cagrilintide?
Neither is universally "better" - the choice depends on your specific goals. Pramlintide is typically used for metabolic purposes, while Cagrilintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Pramlintide and Cagrilintide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Pramlintide and Cagrilintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.